Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MOGAT2 | Q3SYC2 | 18/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclohexane SCHEMBL4184322 | 0.91 | ESR1 (0.42) | MOGAT2ESR1ESR2LMNATP53 | |
| SCHEMBL4200117 | 0.85 | TSHR (0.40) | MOGAT2LMNATP53MAPTTHRB | |
| SCHEMBL4195078 | 0.84 | ALDH1A1 (0.39) | MOGAT2LMNATP53MAPTTHRB | |
| SCHEMBL4186009 | 0.83 | MOGAT2 (0.47) | MOGAT2ESR1ESR2LMNATP53 | |
| SCHEMBL4184464 | 0.82 | MOGAT2 (0.47) | MOGAT2ESR1ESR2LMNATP53 | |
| SCHEMBL14343600 | 0.81 | MOGAT2 (0.43) | MOGAT2ESR1ESR2LMNATP53 | |
| SCHEMBL4197642 | 0.80 | MOGAT2 (0.43) | MOGAT2ESR1ESR2LMNATP53 | |
| Cyclohexane SCHEMBL4193643 | 0.78 | ESR1 (0.46) | MOGAT2ESR1ESR2LMNATP53 | |
| Cyclopentane SCHEMBL4198281 | 0.78 | ESR1 (0.46) | MOGAT2ESR1ESR2LMNATP53 | |
| Cyclohexanol SCHEMBL4191255 | 0.78 | MOGAT2 (0.44) | MOGAT2ESR1ESR2LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | claimed |
| US-20090215764-A1 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | claimed |
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | disclosed |
| US-8076370-B2 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2011-12-13 | — | — | US | disclosed |
| US-20090215764-A1 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215764-A1 | Antimicrobial agents | TUFM, RPS17, HARS1 | MOGAT2 3660/4885ESR1 1212/4885ESR2 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.